Compare FBIZ & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBIZ | MRVI |
|---|---|---|
| Founded | 1909 | 2014 |
| Country | United States | United States |
| Employees | 365 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 437.9M | 472.8M |
| IPO Year | 2012 | 2020 |
| Metric | FBIZ | MRVI |
|---|---|---|
| Price | $51.73 | $3.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $65.00 | $4.00 |
| AVG Volume (30 Days) | 23.3K | ★ 1.2M |
| Earning Date | 04-30-2026 | 05-26-2026 |
| Dividend Yield | ★ 2.59% | N/A |
| EPS Growth | 14.23 | ★ 14.29 |
| EPS | ★ 5.94 | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | $15.69 | $11.80 |
| Revenue Next Year | $8.47 | $7.74 |
| P/E Ratio | $8.84 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $42.18 | $1.67 |
| 52 Week High | $60.54 | $4.11 |
| Indicator | FBIZ | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 29.76 | 38.72 |
| Support Level | $46.71 | $2.88 |
| Resistance Level | $53.17 | $3.99 |
| Average True Range (ATR) | 1.69 | 0.21 |
| MACD | -0.37 | -0.02 |
| Stochastic Oscillator | 11.32 | 2.91 |
First Business Financial Services Inc operates as a bank holding company. The Bank operates as a business bank, delivering a full line of commercial banking products, including commercial loans and commercial real estate loans, to meet the specific needs of small and medium-sized businesses, business owners, executives, professionals, and high-net-worth individuals. The company's products and services include commercial lending, SBA lending and servicing, asset-based lending, equipment financing, factoring, trust, and investment services, treasury management services, and a broad range of deposit products. Geographically, all the business activity functioned through the region of the United States.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.